Literature DB >> 22027658

Mechanisms of disease: hypertrophic cardiomyopathy.

Norbert Frey1, Mark Luedde, Hugo A Katus.   

Abstract

Hypertrophic cardiomyopathy (HCM) is the most-common monogenically inherited form of heart disease, characterized by thickening of the left ventricular wall, contractile dysfunction, and potentially fatal arrhythmias. HCM is also the most-common cause of sudden cardiac death in individuals younger than 35 years of age. Much progress has been made in the elucidation of the genetic basis of HCM, resulting in the identification of more than 900 individual mutations in over 20 genes. Interestingly, most of these genes encode sarcomeric proteins, such as myosin-7 (also known as cardiac muscle β-myosin heavy chain; MYH7), cardiac myosin-binding protein C (MYBPC3), and cardiac muscle troponin T (TNNT2). However, the molecular events that ultimately lead to the clinical phenotype of HCM are still unclear. We discuss several potential pathways, which include altered calcium cycling and sarcomeric calcium sensitivity, increased fibrosis, disturbed biomechanical stress sensing, and impaired cardiac energy homeostasis. An improved understanding of the pathological mechanisms involved will result in greater specificity and success of therapies for patients with HCM.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22027658     DOI: 10.1038/nrcardio.2011.159

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  120 in total

1.  Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.

Authors:  Tetsuo Konno; Dan Chen; Libin Wang; Hiroko Wakimoto; Polakit Teekakirikul; Matthew Nayor; Masataka Kawana; Seda Eminaga; Joshua M Gorham; Kumar Pandya; Oliver Smithies; Francisco J Naya; Eric N Olson; J G Seidman; Christine E Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

2.  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.

Authors:  F Zannad; F Alla; B Dousset; A Perez; B Pitt
Journal:  Circulation       Date:  2000-11-28       Impact factor: 29.690

3.  Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy?

Authors:  T Tanaka; K Sohmiya; K Kawamura
Journal:  J Mol Cell Cardiol       Date:  1997-01       Impact factor: 5.000

4.  Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs.

Authors:  Jan A M Smeitink; Orly Elpeleg; Hana Antonicka; Heleen Diepstra; Ann Saada; Paulien Smits; Florin Sasarman; Gert Vriend; Jasmine Jacob-Hirsch; Avraham Shaag; Gideon Rechavi; Brigitte Welling; Jurgen Horst; Richard J Rodenburg; Bert van den Heuvel; Eric A Shoubridge
Journal:  Am J Hum Genet       Date:  2006-09-15       Impact factor: 11.025

Review 5.  Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients.

Authors:  Barry J Maron; Magdi Yacoub; Joseph A Dearani
Journal:  Eur Heart J       Date:  2011-02-14       Impact factor: 29.983

6.  Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells.

Authors:  Sebastian E Kirschner; Edgar Becker; Massimo Antognozzi; Hans-Peter Kubis; Antonio Francino; Francisco Navarro-López; Nana Bit-Avragim; Andreas Perrot; Mirsaid M Mirrakhimov; Karl-Josef Osterziel; William J McKenna; Bernhard Brenner; Theresia Kraft
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-11-18       Impact factor: 4.733

7.  Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling.

Authors:  Björn C Knollmann; Paulus Kirchhof; Syevda G Sirenko; Hubertus Degen; Anne E Greene; Tilmann Schober; Jessica C Mackow; Larissa Fabritz; James D Potter; Martin Morad
Journal:  Circ Res       Date:  2003-02-06       Impact factor: 17.367

8.  HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.

Authors:  J Bauersachs; S Störk; M Kung; C Waller; F Fidler; C Hoyer; S Frantz; F Weidemann; G Ertl; C E Angermann
Journal:  Eur J Clin Invest       Date:  2007-11       Impact factor: 4.686

9.  Histologic characterization of hypertrophic cardiomyopathy with and without myofilament mutations.

Authors:  Christopher J McLeod; J Martijn Bos; Jeanne L Theis; William D Edwards; Bernard J Gersh; Steve R Ommen; Michael J Ackerman
Journal:  Am Heart J       Date:  2009-10-03       Impact factor: 4.749

10.  Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice.

Authors:  Franz Baudenbacher; Tilmann Schober; Jose Renato Pinto; Veniamin Y Sidorov; Fredrick Hilliard; R John Solaro; James D Potter; Björn C Knollmann
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

View more
  92 in total

1.  Early remodeling of repolarizing K+ currents in the αMHC403/+ mouse model of familial hypertrophic cardiomyopathy.

Authors:  Rocco Hueneke; Adam Adenwala; Rebecca L Mellor; Jonathan G Seidman; Christine E Seidman; Jeanne M Nerbonne
Journal:  J Mol Cell Cardiol       Date:  2017-01-13       Impact factor: 5.000

2.  Gene expression analyses of mouse aortic endothelium in response to atherogenic stimuli.

Authors:  Ayca Erbilgin; Nathan Siemers; Paul Kayne; Wen-pin Yang; Judith Berliner; Aldons J Lusis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-08-29       Impact factor: 8.311

3.  Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.

Authors:  Sarah A Clay; Timothy L Domeier; Laurin M Hanft; Kerry S McDonald; Maike Krenz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

Review 4.  MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction.

Authors:  Verena Behrens-Gawlik; Giulia Mearini; Christina Gedicke-Hornung; Pascale Richard; Lucie Carrier
Journal:  Pflugers Arch       Date:  2013-12-12       Impact factor: 3.657

5.  Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function.

Authors:  Ruth F Sommese; Jongmin Sung; Suman Nag; Shirley Sutton; John C Deacon; Elizabeth Choe; Leslie A Leinwand; Kathleen Ruppel; James A Spudich
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

6.  Nonlinear cross-bridge elasticity and post-power-stroke events in fast skeletal muscle actomyosin.

Authors:  Malin Persson; Elina Bengtsson; Lasse ten Siethoff; Alf Månsson
Journal:  Biophys J       Date:  2013-10-15       Impact factor: 4.033

7.  Late enhanced computed tomography in Hypertrophic Cardiomyopathy enables accurate left-ventricular volumetry.

Authors:  Christoph Langer; M Both; H Harders; M Lutz; M Eden; C Kühl; B Sattler; O Jansen; P Schaefer; N Frey
Journal:  Eur Radiol       Date:  2014-10-15       Impact factor: 5.315

Review 8.  Proteasome dysfunction in cardiomyopathies.

Authors:  Jennifer E Gilda; Aldrin V Gomes
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

9.  Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.

Authors:  Marco L Alves; Fernando A L Dias; Robert D Gaffin; Jillian N Simon; Eric M Montminy; Brandon J Biesiadecki; Aaron C Hinken; Chad M Warren; Megan S Utter; Robert T Davis; Sadayappan Sakthivel; Jeffrey Robbins; David F Wieczorek; R John Solaro; Beata M Wolska
Journal:  Circ Cardiovasc Genet       Date:  2014-02-28

Review 10.  Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse.

Authors:  Brian R Berridge; Vasanthi Mowat; Hirofumi Nagai; Abraham Nyska; Yoshimasa Okazaki; Peter J Clements; Matthias Rinke; Paul W Snyder; Michael C Boyle; Monique Y Wells
Journal:  J Toxicol Pathol       Date:  2016-07-29       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.